Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Employees

Sector

Biotechnology & Medical Research

More about the company

Jun. 14	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis	CI
May. 28	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer	CI
May. 25	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting	CI
Dec. 08	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	CI
Nov. 24	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS	CI
25-03-20	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm	CI
24-12-11	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela	CI
23-12-11	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	CI
23-12-08	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	CI
23-11-20	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	CI
23-10-30	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	CI
23-09-20	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	CI
23-05-25	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	CI

20-12-17	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
20-06-10	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-05-11	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
20-05-05	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
20-05-04	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

19-01-16	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19-01-16	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Ivan Bergstein CEO	Chief Executive Officer	60	-
David Gionco DFI	Director of Finance/CFO	65	2014-01-15
Nassir Habboubi CTO	Chief Tech/Sci/R&D Officer	-	2020-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/10/20	Ivan Bergstein	Free	Chief Executive Officer	3,872,092	7.3739%
6/10/20	Robert Francomano	Tender	Executive/Senior Manager	250,891	0.4778%
6/10/20	Ron Bentsur	Tender	Director	151,450	0.2884%

Stemline Therapeutics, Inc. Stock

Stocks

US85858C1071

Biotechnology & Medical Research

Latest news: Stemline Therapeutics, Inc.

Press Releases: Stemline Therapeutics, Inc.

News in other languages: Stemline Therapeutics, Inc.

Managers and Directors: Stemline Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMLINE THERAPEUTICS, INC.	-.--%	-.--%	-	-	570M
WUXI APPTEC CO., LTD.	-0.21%	-4.43%	+44.40%	+74.13%	66.22B
ARGENX SE	-3.81%	-0.47%	+6.46%	+67.44%	55.2B
LONZA GROUP AG	+0.14%	+3.35%	+11.43%	+90.48%	52.79B
IQVIA HOLDINGS INC.	+3.28%	+5.58%	+26.51%	+50.05%	45.53B
BEONE MEDICINES AG	+0.51%	+9.95%	+22.40%	+133.92%	43.94B
REVOLUTION MEDICINES, INC.	-1.15%	+0.39%	+263.21%	+594.60%	41.64B
CELLTRION, INC.	+0.10%	+9.90%	+16.11%	+59.33%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-6.95%	+26.35%	-1.93%	25.84B
GENMAB A/S	-0.69%	+2.73%	+35.31%	+25.33%	23.51B
Average	-1.04%	+4.07%	+50.24%	+121.48%	43.19B
Weighted average by Cap.	-0.86%	+3.72%	+49.17%	+125.80%